688606 Hangzhou Alltest Biotech
- 66.50
- -1.42-2.09%
Hangzhou Alltest Biotech News
Aotai Biotech (688606.SH)'s net profit of 44.79 million yuan in the first quarter increased 10.50% year-on-year
Gelonghui, April 26 | Aotai Biotech (688606.SH) announced that in the first quarter of 2024, the company's revenue was 200 million yuan, a year-on-year decrease of 15.34%; net profit attributable to shareholders of listed companies was 44.79 million yuan, an increase of 10.50% over the previous year; and basic earnings per share were 0.56 yuan/share.
Revenues Not Telling The Story For Hangzhou Alltest Biotech Co., Ltd. (SHSE:688606)
It's not a stretch to say that Hangzhou Alltest Biotech Co., Ltd.'s (SHSE:688606) price-to-sales (or "P/S") ratio of 6.5x seems quite "middle-of-the-road" for Medical Equipment companies in China, se
Aotai Biotech (688606.SH): The ban on 2.092,900 restricted shares was lifted on March 25
Gelonghui March 14 | Aotai Biotech (688606.SH) announced that the total number of shares in circulation during the current stock listing of the company is 2.092,900 shares. The stock listing and circulation date is March 25, 2024.
Is Hangzhou Alltest Biotech Co., Ltd.'s (SHSE:688606) Stock Price Struggling As A Result Of Its Mixed Financials?
With its stock down 20% over the past three months, it is easy to disregard Hangzhou Alltest Biotech (SHSE:688606). It is possible that the markets have ignored the company's differing financials an
Aotai Biotech (688606.SH) completed the repurchase and spent 595.75,500 yuan to repurchase 1.03 million shares
Aotai Biotech (688606.SH) announced that the company has completed the repurchase and has actually repurchased 1.03 million shares of the company's shares, accounting for...
Aotai Biotech (688606.SH)'s net profit for 2023 was 180 million yuan, a sharp decrease of 84.8%
Aotai Biotech (688606.SH) disclosed the 2023 annual results report, and the company achieved a total operating revenue of 7.55...
Aotai Biotech (688606.SH): It spent 53.432 million yuan to buy back a total of 1.1651% of the shares
Gelonghui, January 31, 丨 Aotai Biotech (688606.SH) announced that as of January 31, 2024, the company had repurchased a total of 923,700 shares of the company's shares through centralized bidding transactions, accounting for 1.1651% of the company's total share capital of 79,280,855 shares, an increase of 0.6606% compared with the previous disclosure. The highest price of the repurchase transaction was 60.00 yuan/share, the lowest price was 55.11 yuan/share, and the total capital paid was RMB 53.432 million (excluding stamp duty, transaction commissions, etc.) transaction fees).
Aotai Biotech (688606.SH): Net profit is expected to drop 85.23% year on year to 86.07% in 2023
Gelonghui, January 26丨Aotai Biotech (688606.SH) announced that according to preliminary estimates by the financial department, Hangzhou Aotai Biotechnology Co., Ltd. is expected to achieve operating income of 747 million yuan to 757 million yuan in 2023. Compared with the same period last year (statutory disclosure data), it will decrease 2631.57 million yuan to 2641.57 million yuan, a year-on-year decrease of 77.66% to 77.96%. In 2023, net profit attributable to owners of the parent company is expected to reach 165 million yuan to 175 million yuan. Compared with the same period of the previous year (statutory disclosure data), it will
Aotai Biotech (688606.SH): A total cost of 22.64 million yuan to buy back 0.5% of shares
Gelonghui, January 2, 丨 Aotai Biotech (688606.SH) announced that as of December 31, 2023, the company had repurchased 400,000 shares of the company's shares through centralized bidding transactions, accounting for 0.5045% of the company's total share capital of 79,280,855 shares. The highest price of the repurchase transaction was 58.01 yuan/share, the lowest price was 55.11 yuan/share, and the total amount of capital paid was RMB 22,641,640.33.
Aotai Biotech (688606.SH): Repurchased 400,000 shares at a total cost of 22.64 million yuan
Gelonghui (688606.SH) announced on November 1 | Aotai Biotech () announced that as of October 31, 2023, the company has repurchased a total of 400,000 shares of the company's shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.5045% of the company's total share capital of 79,280,855 shares. The highest repurchase transaction price is 58.01 yuan/share, the lowest price is 55.11 yuan/share, and the total capital paid is RMB 22,641,640.33.
Aotai Biotech (688606.SH): A total of 400,000 shares have been repurchased by the end of September
Glonghui, October 10, 丨 Aotai Biotech (688606.SH) announced that as of September 30, 2023, the company had repurchased 400,000 shares of the company through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.5045% of the company's total share capital of 79,280,855 shares. The highest repurchase price was 58.01 yuan/share, the lowest price was 55.11 yuan/share, and the total amount of capital paid was RMB 22,641,640.33 (excluding transaction fees such as stamp duty and transaction fees).
Aotai Biotech (688606.SH): At a cost of 22.641,600 yuan, a total of 400,000 shares have been repurchased
Glonghui September 27丨Aotai Biotech (688606.SH) announced that as of the close of trading on September 27, 2023, the company had repurchased 400,000 shares of the company through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.5045% of the company's total share capital of 79,280,855 shares. The highest repurchase price was 58.01 yuan/share, the lowest price was 55.11 yuan/share, and the total amount of capital paid was RMB 22.641,600 (excluding transaction fees such as stamp duty and transaction fees).
Aotai Biotech (688606.SH): The company has not implemented a share repurchase
Glonghui September 4 丨 Aotai Biotech (688606.SH) announced that as of August 31, 2023, the company has not implemented a share repurchase.
Lu Weike, director of Aotai Biotech (688606.SH), has not reduced his holdings at the end of the holdings reduction period
According to the Zhitong Finance App, Aotai Biotech (688606.SH) announced that Lu Wei, the company's director, senior manager, and core technician, has reduced his holdings of the company by a total of 0 shares, accounting for 0% of the company's total share capital. As of the disclosure date of this announcement, the time period for the current holdings reduction plan has expired.
Aotai Biotech's “downhill road” in the post-pandemic era
“Investor Network” Zhang Wei In the post-pandemic era, how many companies that once relied on the COVID-19 pandemic to improve their performance still have? The answer can be seen from the newly disclosed quarterly reports. On April 29, the in vitro diagnostic reagent manufacturer Hangzhou Aotai Biotechnology Co., Ltd. (hereinafter referred to as “Aotai Biotech”, 688606.SH) released a quarterly report showing that the company's revenue for the first quarter of this year (Q1) fell 88.75% year on year, and net profit fell 96.14% year on year, in stark contrast to 2022 revenue and net profit, which increased 80.88% and 54.69% respectively. On the secondary market, on Alotai Biotech
The latest announcement of Huahai Pharmaceutical Co., Ltd.: plans to implement the second phase of employee equity incentive for China Aotai Biology.
Huahai Pharmaceutical announced that it intends to implement the second phase of employee equity incentive to its subsidiary Huaotai Biology. The incentive targets are the senior managers, core staff and other employees that the company believes should be encouraged in China Aotai Biology and its subsidiaries; the incentive share comes from the 4.6437% equity of Huaotai Biology Company (a total of 20.177732 million shares) transferred by the company to Huaotai Biological employee shareholding platform. The chairman of the company is Li Hong. Mr. Li Hong: bachelor degree, Deputy Director of the Industrial Promotion Center of the Ministry of Industry and Information Technology from January 2015 to July 2017; August 2017 to 2017 1
The main force of Aotai Biology bought 4.5183 million yuan net on January 19th.
As of January 19, 2022, Aotai Bio (688606) closed at 161.5 yuan, down 8.16%, with a turnover rate of 24.19%, with a turnover of 31600 lots and a turnover of 517 million yuan. In terms of capital flow data, the net inflow of main funds on the same day was 4.5183 million yuan, the net outflow of hot capital was 3.81 million yuan, and the net outflow of retail funds was 5.5104 million yuan. The flow of funds in the past five days is shown in the following table: Aotai biological margin information shows that in terms of financing, financing bought 44.3615 million yuan on the same day, repaid 30.6038 million yuan, and net bought 1.
COVID-19 testing plate fell, while 688606.CN fell 20.0%.
[Caihua Social News] at midday today, as of 13:15, COVID-19 testing plate fell. 688606.CN fell 20.00% to 175.84 yuan, 688767.CN fell 16.69% to 102.06 yuan, 688068.CN fell 15.71% to 176.0 yuan, Guangshengtang (300436.CN) fell 15.45% to 45.04 yuan, 300482.CN fell 13.59% to 45.54 yuan, and Haishun new material (300501.CN) fell 13.42
The medical device sector fell, and 688606.CN fell 20.0%.
[Caihua Social News] at midday today, as of 13:15, the medical device plate fell. 688606.CN fell 20.00% to 175.84 yuan, 688075.CN fell 17.50% to 232.64 yuan, 688767.CN fell 16.69% to 102.06 yuan, 688068.CN fell 15.71% to 176.0 yuan, 688575.CN fell 14.33% to 38.98 yuan, 300482.CN fell 13.5%
Abnormal KuaiBao: Aotai Biology (688606) closed the falling limit at 11:03 on January 18th.
Intraday news on January 18, 11:03 Aotai Biological (688606) closed the limit. The current price is 175.84, down 20.0%. The medical devices of the plate to which it belongs are currently falling. Lead the stock for Jianfan creature. The main indicators and industry rankings of Aotai Biology are as follows: Aotai Biology (688606) Stock Overview: this article is compiled by Securities Star data Center according to public data, and does not constitute investment opinions or suggestions. If you have any questions, please contact us.
Analysis
Price Target
No Data
